Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $5.3150 (-1.39%) ($5.3150 - $5.3150) on Wed. May. 12, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.23% (three month average) | RSI | 52 | Latest Price | $5.3150(-1.39%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | ADMS declines -0.4% a day on average for past five trading days. | Weekly Trend | ADMS declines -4.6% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability) EWG(31%) EWP(22%) OIH(9%) IFRA(8%) JETS(16%) | Factors Impacting ADMS price | ADMS will decline at least -2.115% in a week (0% probabilities). TLT(-61%) TAN(-15%) SMH(-13%) ACES(-12%) XHB(-7%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.115% (StdDev 4.23%) | Hourly BBV | 0.2 () | Intraday Trend | 0% | | | |
|
Resistance Level | $5.4 | 5 Day Moving Average | $5.16(3%) | 10 Day Moving Average | $5.37(-1.02%) | 20 Day Moving Average | $5.4(-1.57%) | To recent high | -11.3% | To recent low | 6.1% | Market Cap | $150m | | | | Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |